Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 20, 2020 16:02 ET | Source: Nkarta, Inc.

Nkarta Reports Second Quarter 2020 Financial Results

Co-Lead programs on track: NKX101 expected to begin Phase 1 dosing in 4Q 2020 and IND for NKX019 expected to be filed in 1Q 2021Completed construction of cGMP clinical manufacturing facilityCompleted...
July 14, 2020 16:15 ET | Source: Nkarta, Inc.

Nkarta Announces Closing of Upsized Initial Public Offering and Exercise in Full of Underwriters' Option to Purchase Additional Shares

SOUTH SAN FRANCISCO, Calif., July 14, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to...
July 10, 2020 00:44 ET | Source: Nkarta, Inc.

Nkarta Announces Pricing of Initial Public Offering

SOUTH SAN FRANCISCO, July 10, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
June 22, 2020 09:52 ET | Source: Nkarta

Nkarta Therapeutics Presents Preclinical Findings Supporting Gene Editing of Natural Killer Cells and the Combination of Engineered NK plus T Cells at the American Association for Cancer Research (AACR) Virtual 2020 Annual Meeting II

Gene editing of engineered natural killer cells contributed to enhanced cell persistence and tumor killing Combination of engineered natural killer cells and engineered T cells demonstrated potential...
April 27, 2020 08:30 ET | Source: Nkarta

Nkarta Therapeutics Appoints Two New Independent Directors

SOUTH SAN FRANCISCO, Calif., April 27, 2020 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nkarta), a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
January 09, 2020 08:00 ET | Source: Nkarta

Nkarta Therapeutics to Present at the J.P. Morgan Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat...
December 09, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Expands Senior Management Team with Key Hires in Finance and Clinical Development

SOUTH SAN FRANCISCO, Calif., Dec. 09, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
November 18, 2019 17:16 ET | Source: Nkarta

Nkarta Therapeutics Presents Preclinical Data for CD19 CAR NK Program

SOUTH SAN FRANCISCO, Calif., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 23, 2019 09:00 ET | Source: Nkarta

Nkarta Therapeutics Named as a “Fierce 15” Biotechnology Company of 2019

SOUTH SAN FRANCISCO, Calif., Sept. 23, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...
September 18, 2019 08:00 ET | Source: Nkarta

Nkarta Therapeutics Promotes Nadir Mahmood, Ph.D., to Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Sept. 18, 2019 (GLOBE NEWSWIRE) -- Nkarta Therapeutics, a privately-held biopharmaceutical company developing engineered natural killer (NK) cell therapies to fight...